Vermillion, Quest Ink Deal to Sell OVA1 in India | GenomeWeb

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Vermillion today announced an agreement with Quest Diagnostics for the launch of the OVA1 ovarian cancer test in India.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.